PDCD1 and soft tissue sarcoma: For instance, in the PEMBROSARC trial in adult soft-tissue sarcoma patients, pembrolizumab (an anti-PD-1 agent) was administered in combination with low-dose cyclophosphamide to patients selected based on the presence of tertiary lymphoid structures (TLS) [102,103].